Computational modeling of ovarian cancer dynamics suggests optimal strategies for therapy and screening
- 14 June 2021
- journal article
- research article
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 118 (25)
Abstract
Significance: The optimal timing of surgery/chemotherapy and the benefits of earlier diagnosis of HGSC remain controversial. We developed a mathematical framework of tumor dynamics, populated the model with primary clinical data, and reliably recapitulated clinical observations. Our model predicts that 1) PDS is superior to NACT with relatively small tumor burden and when complete debulking is feasible, 2) timely adjuvant chemotherapy is critical for the outcome of PDS with <1-mm residual tumors, 3) earlier detection of relapse is unlikely beneficial with current therapies, and 4) earlier detection of primary HGSC could have substantial benefit. These results provide insights into the evolutionary dynamics of HGSC, argue for new clinical trials to optimize therapy, and are potentially applicable to other tumor types.Keywords
All Related Versions
Funding Information
- Terry Fox Foundation (TFPPG 020003)
- HHS | NIH | National Cancer Institute (R37 49152)
- HHS | NIH | National Cancer Institute (R01257507)
- Mary Kay Ash Foundation (XXX)
- Sara Elizabeth O'Brien Trust (XXX)
- University of Toronto (DCA Award)
- HHS | NIH | National Cancer Institute (P30 CA008748)
- Ontario Ministry of Health and Long-Term Care (XXX)
- Princess Margaret Cancer Foundation (XXX)
This publication has 79 references indexed in Scilit:
- Evolutionary dynamics of cancer in response to targeted combination therapyeLife, 2013
- The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancersNature, 2012
- Whole-genome analysis informs breast cancer response to aromatase inhibitionNature, 2012
- Dynamics of targeted cancer therapyTrends in Molecular Medicine, 2012
- Computational Modeling of Pancreatic Cancer Reveals Kinetics of Metastasis Suggesting Optimum Treatment StrategiesCell, 2012
- Optimization of Dosing for EGFR-Mutant Non–Small Cell Lung Cancer with Evolutionary Cancer ModelingScience Translational Medicine, 2011
- Phenotypic heterogeneity and instability of human ovarian tumor-initiating cellsProceedings of the National Academy of Sciences, 2011
- Assessing Lead Time of Selected Ovarian Cancer Biomarkers: A Nested Case–Control StudyJNCI: Journal of the National Cancer Institute, 2010
- Evolution of Resistance During Clonal ExpansionGenetics, 2006
- Drug resistance in cancer: Principles of emergence and preventionProceedings of the National Academy of Sciences, 2005